With the increasing importance of early diagnosis in disease, there is a need for quicker and easier diagnosis techniques. Various immunological diagnostic methods are being studied and developed. Advancement of diagnostic methods presents higher sensitivity, specificity and convenience. GCMS Immunodiagnostics is continuously expanding its domestic market share on the basis of its diverse product portfolio. To target the immunodiagnostic market, the largest market in the global diagnostic reagent field, we take persistent efforts in development and diversification of our product portfolio. We will enhance our competitiveness and increase revenue by development of raw materials for diagnosis.
GCMS will be a domestically and globally well-recognized leading company dedicated to diagnostics.

Molecular diagnosis is a method of measuring the presence and concentration of nucleic acids (DNA, RNA), which are the most basic units of genetic material that comprise an organism.
There has been fastest ever technology development in recent years, and various new products are being developed. The demand has increased rapidly in domestic and overseas markets because of the COVID-19 pandemic.
Molecular diagnosis is the fastest way to respond to new pandemic situations and it has become a standard for determining infection of disease thanks to its high accuracy.
GCMS continues to research and develop molecular diagnostic reagents.
We are developing a portfolio of products that can quickly and accurately diagnose infectious diseases (pandemic), cancer, genetic diseases, and various other malignant diseases that cause long-term pain to people.

Recently, the needs for POCT capable of rapid testing at the field are increasing. GC Green Cross Medical Science is developing highly reliable diagnostic devices. In addition, we expand our scope of R&D to data transmission using wireless communication and data management using cloud servers.